Coho Partners Ltd. lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,000 shares of the biopharmaceutical company’s stock after selling 1,100 shares during the quarter. Coho Partners Ltd.’s holdings in Bristol-Myers Squibb were worth $632,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. Hunter Associates Investment Management LLC lifted its holdings in Bristol-Myers Squibb by 4.4% during the fourth quarter. Hunter Associates Investment Management LLC now owns 18,488 shares of the biopharmaceutical company’s stock valued at $1,133,000 after purchasing an additional 780 shares during the last quarter. Harwood Advisory Group LLC lifted its holdings in Bristol-Myers Squibb by 11.4% during the fourth quarter. Harwood Advisory Group LLC now owns 7,784 shares of the biopharmaceutical company’s stock valued at $476,000 after purchasing an additional 799 shares during the last quarter. Howard Capital Management lifted its holdings in Bristol-Myers Squibb by 0.5% during the fourth quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 804 shares during the last quarter. Staley Capital Advisers Inc. lifted its holdings in Bristol-Myers Squibb by 11.7% during the third quarter. Staley Capital Advisers Inc. now owns 7,801 shares of the biopharmaceutical company’s stock valued at $497,000 after purchasing an additional 817 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Bristol-Myers Squibb by 0.8% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 105,519 shares of the biopharmaceutical company’s stock valued at $6,466,000 after purchasing an additional 818 shares during the last quarter. Institutional investors own 71.29% of the company’s stock.
Bristol-Myers Squibb opened at $52.71 on Monday, Marketbeat Ratings reports. The company has a current ratio of 1.52, a quick ratio of 1.39 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $86.16 billion, a P/E ratio of 16.95, a P/E/G ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. Bristol-Myers Squibb’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.84 earnings per share. sell-side analysts predict that Bristol-Myers Squibb Co will post 3.41 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Several equities research analysts have commented on BMY shares. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $51.56 to $78.00 in a report on Thursday, February 15th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. Jefferies Group set a $70.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Friday, March 23rd. BMO Capital Markets reissued a “sell” rating and issued a $52.00 price target on shares of Bristol-Myers Squibb in a report on Monday, January 22nd. Finally, Argus reissued a “buy” rating and issued a $66.43 price target (down from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday, March 21st. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $63.68.
In related news, Director Dinesh C. Paliwal acquired 4,770 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The shares were bought at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the transaction, the director now owns 8,027 shares in the company, valued at $420,614.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.12% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.